{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:14:40Z","timestamp":1740107680456,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T00:00:00Z","timestamp":1472083200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003035","name":"the Aase and Ejnar Danielsen Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Danish Rheumatism Association","award":["R107-A2336"],"award-info":[{"award-number":["R107-A2336"]}]},{"name":"the Department of Pediatrics, Naestved Hospital, Region Zealand"},{"name":"the Research Department, Region Zealand"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s10067-016-3375-x","type":"journal-article","created":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T03:41:18Z","timestamp":1472096478000},"page":"67-75","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Low pretreatment levels of myeloid-related protein-8\/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis"],"prefix":"10.1007","volume":"36","author":[{"given":"Mikel","family":"Alberdi-Saugstrup","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pernille","family":"Mathiessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus Henrik","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,25]]},"reference":[{"issue":"10","key":"3375_CR1","first-page":"2275","volume":"30","author":"L Berntson","year":"2003","unstructured":"Berntson L, Andersson GB, Fasth A, Herlin T, Kristinsson J, Lahdenne P, et al. (2003) Incidence of juvenile idiopathic arthritis in the Nordic countries. A population based study with special reference to the validity of the ILAR and EULAR criteria. J Rheumatol 30(10):2275\u20132282","journal-title":"J Rheumatol"},{"issue":"2","key":"3375_CR2","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390\u2013392","journal-title":"J Rheumatol"},{"issue":"16","key":"3375_CR3","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","volume":"326","author":"EH Giannini","year":"1992","unstructured":"Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. (1992) Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children\u2019s Study Group. N Engl J Med 326(16):1043\u20131049","journal-title":"N Engl J Med"},{"issue":"4","key":"3375_CR4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. (2011) 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken ) 63(4):465\u2013482","journal-title":"Arthritis Care Res (Hoboken )"},{"key":"3375_CR5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fphar.2011.00060","volume":"2","author":"N Ruperto","year":"2011","unstructured":"Ruperto N, Martini A (2011) Current medical treatments for juvenile idiopathic arthritis. Front Pharmacol 2:60","journal-title":"Front Pharmacol"},{"issue":"5","key":"3375_CR6","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2014.212","volume":"11","author":"C Hinze","year":"2015","unstructured":"Hinze C, Gohar F, Foell D (2015) Management of juvenile idiopathic arthritis: hitting the target. Nat Rev Rheumatol 11(5):290\u2013300","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"3375_CR7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/ard.62.3.245","volume":"62","author":"P Lahdenne","year":"2003","unstructured":"Lahdenne P, Vahasalo P, Honkanen V (2003) Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 62(3):245\u2013247","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"3375_CR8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342(11):763\u2013769","journal-title":"N Engl J Med"},{"issue":"5","key":"3375_CR9","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","volume":"58","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al. (2008) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58(5):1496\u20131504","journal-title":"Arthritis Rheum"},{"issue":"8","key":"3375_CR10","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359(8):810\u2013820","journal-title":"N Engl J Med"},{"issue":"4","key":"3375_CR11","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.2009.100354","volume":"69","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, et al. (2010) Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 69(4):718\u2013722","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3375_CR12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/ard.2007.087593","volume":"68","author":"G Horneff","year":"2009","unstructured":"Horneff G, De BF, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 68(4):519\u2013525","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"3375_CR13","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.38741","volume":"66","author":"H Schmeling","year":"2014","unstructured":"Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G (2014) Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol 66(9):2580\u20132589","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"3375_CR14","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.2007.087411","volume":"68","author":"FH Prince","year":"2009","unstructured":"Prince FH, Twilt M, Ten CR, van Rossum MA, Armbrust W, Hoppenreijs EP, et al. (2009) Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 68(5):635\u2013641","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"3375_CR15","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.2011.1671","volume":"306","author":"MH Otten","year":"2011","unstructured":"Otten MH, Prince FH, Armbrust W, Ten CR, Hoppenreijs EP, Twilt M, et al. (2011) Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 306(21):2340\u20132347","journal-title":"JAMA"},{"key":"3375_CR16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13075-015-0723-1","volume":"17","author":"J Anink","year":"2015","unstructured":"Anink J, van Suijlekom-Smit LW, Otten MH, Prince FH, van Rossum MA, Dolman KM, et al. (2015) MRP8\/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Arthritis Res Ther 17:200","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"3375_CR17","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/rheumatology\/ket490","volume":"53","author":"T Geikowski","year":"2014","unstructured":"Geikowski T, Becker I, Horneff G (2014) Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis. Rheumatology (Oxford) 53(7):1245\u20131249","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"3375_CR18","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4081\/reumatismo.2013.682","volume":"65","author":"M Romano","year":"2013","unstructured":"Romano M, Pontikaki I, Gattinara M, Ardoino I, Donati C, Boracchi P, et al. (2013) Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients. Reumatismo 65(6):278\u2013285","journal-title":"Reumatismo"},{"issue":"4","key":"3375_CR19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/ard.2007.087130","volume":"68","author":"P Tynjala","year":"2009","unstructured":"Tynjala P, Vahasalo P, Honkanen V, Lahdenne P (2009) Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. Ann Rheum Dis 68(4):552\u2013557","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3375_CR20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/rheumatology\/keq308","volume":"50","author":"TR Southwood","year":"2011","unstructured":"Southwood TR, Foster HE, Davidson JE, Hyrich KL, Cotter CB, Wedderburn LR, et al. (2011) Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford) 50(1):189\u2013195","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"3375_CR21","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3899\/jrheum.120842","volume":"40","author":"N Solari","year":"2013","unstructured":"Solari N, Palmisani E, Consolaro A, Pistorio A, Viola S, Buoncompagni A, et al. (2013) Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 40(2):192\u2013200","journal-title":"J Rheumatol"},{"issue":"14","key":"3375_CR22","doi-asserted-by":"crossref","first-page":"9496","DOI":"10.1074\/jbc.272.14.9496","volume":"272","author":"A Rammes","year":"1997","unstructured":"Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C (1997) Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 272(14):9496\u20139502","journal-title":"J Biol Chem"},{"issue":"2","key":"3375_CR23","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000236177","volume":"98","author":"J Roth","year":"1992","unstructured":"Roth J, Sunderkotter C, Goebeler M, Gutwald J, Sorg C (1992) Expression of the calcium-binding proteins MRP8 and MRP14 by early infiltrating cells in experimental contact dermatitis. Int Arch Allergy Immunol 98(2):140\u2013145","journal-title":"Int Arch Allergy Immunol"},{"key":"3375_CR24","doi-asserted-by":"crossref","first-page":"542363","DOI":"10.1155\/2013\/542363","volume":"2013","author":"G Vaos","year":"2013","unstructured":"Vaos G, Kostakis ID, Zavras N, Chatzemichael A (2013) The role of calprotectin in pediatric disease. Biomed Res Int 2013:542363","journal-title":"Biomed Res Int"},{"issue":"3","key":"3375_CR25","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/1529-0131(200003)43:3<628::AID-ANR20>3.0.CO;2-X","volume":"43","author":"M Frosch","year":"2000","unstructured":"Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkotter C, et al. (2000) Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 43(3):628\u2013637","journal-title":"Arthritis Rheum"},{"issue":"5","key":"3375_CR26","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3899\/jrheum.140628","volume":"42","author":"M Abildtrup","year":"2015","unstructured":"Abildtrup M, Kingsley GH, Scott DL (2015) Calprotectin as a biomarker for rheumatoid arthritis: a systematic review. J Rheumatol 42(5):760\u2013770","journal-title":"J Rheumatol"},{"issue":"9","key":"3375_CR27","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/art.11177","volume":"48","author":"M Frosch","year":"2003","unstructured":"Frosch M, Vogl T, Seeliger S, Wulffraat N, Kuis W, Viemann D, et al. (2003) Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 48(9):2622\u20132626","journal-title":"Arthritis Rheum"},{"issue":"12","key":"3375_CR28","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1002\/art.20631","volume":"50","author":"D Foell","year":"2004","unstructured":"Foell D, Roth J (2004) Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 50(12):3762\u20133771","journal-title":"Arthritis Rheum"},{"issue":"13","key":"3375_CR29","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2010.375","volume":"303","author":"D Foell","year":"2010","unstructured":"Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J, et al. (2010) Methotrexate withdrawal at 6 vs 12\u00a0months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303(13):1266\u20131273","journal-title":"JAMA"},{"issue":"12","key":"3375_CR30","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1136\/annrheumdis-2012-201329","volume":"71","author":"J Gerss","year":"2012","unstructured":"Gerss J, Roth J, Holzinger D, Ruperto N, Wittkowski H, Frosch M, et al. (2012) Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Ann Rheum Dis 71(12):1991\u20131997","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3375_CR31","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/rheumatology\/ket152","volume":"52","author":"H Moncrieffe","year":"2013","unstructured":"Moncrieffe H, Ursu S, Holzinger D, Patrick F, Kassoumeri L, Wade A, et al. (2013) A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8\/14 protein. Rheumatology (Oxford) 52(8):1467\u20131476","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"3375_CR32","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","volume":"111","author":"MB Pepys","year":"2003","unstructured":"Pepys MB, Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Invest 111(12):1805\u20131812","journal-title":"J Clin Invest"},{"issue":"6","key":"3375_CR33","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199902113400607","volume":"340","author":"C Gabay","year":"1999","unstructured":"Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340(6):448\u2013454","journal-title":"N Engl J Med"},{"key":"3375_CR34","series-title":"Textbook of Pediatric Rheumatology","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/B978-0-323-24145-8.00015-6","volume-title":"Textbook of pediatric rheumatology","author":"RE Petty","year":"2016","unstructured":"Petty RE, Laxer RM, Lindsley CB, LR. W (2016) Textbook of pediatric rheumatology, Textbook of Pediatric Rheumatology, 7th edn. Elsevier-Saunders, Philadelphia, pp. 188\u2013204","edition":"7"},{"issue":"7","key":"3375_CR35","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1136\/annrheumdis-2011-200237","volume":"71","author":"EB Nordal","year":"2012","unstructured":"Nordal EB, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, et al. (2012) Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting. Ann Rheum Dis 71(7):1122\u20131127","journal-title":"Ann Rheum Dis"},{"issue":"9563","key":"3375_CR36","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A (2007) Juvenile idiopathic arthritis. Lancet 369(9563):767\u2013778","journal-title":"Lancet"},{"issue":"3","key":"3375_CR37","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/art.20946","volume":"52","author":"BF De","year":"2005","unstructured":"De BF, Martini A (2005) Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? Arthritis Rheum 52(3):687\u2013693","journal-title":"Arthritis Rheum"},{"issue":"7","key":"3375_CR38","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40(7):1202\u20131209","journal-title":"Arthritis Rheum"},{"issue":"7","key":"3375_CR39","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/acr.20497","volume":"63","author":"CA Wallace","year":"2011","unstructured":"Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N (2011) American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken ) 63(7):929\u2013936","journal-title":"Arthritis Care Res (Hoboken )"},{"issue":"3","key":"3375_CR40","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140(3):509\u2013516","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"3375_CR41","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1136\/annrheumdis-2014-205265","volume":"74","author":"EH Dijkhuizen van","year":"2015","unstructured":"van Dijkhuizen EH, Wulffraat NM (2015) Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review. Ann Rheum Dis 74(11):1996\u20132005","journal-title":"Ann Rheum Dis"},{"key":"3375_CR42","volume-title":"Encyclopedia of. Biostatistics 1","author":"DV Lindley","year":"2005","unstructured":"Lindley DV (2005) Bayes\u2019 theorem. In: Armitage P, Colton T (eds) Encyclopedia of. Biostatistics 1. Wiley, Minehead UK"},{"issue":"2","key":"3375_CR43","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1006\/bbrc.1993.1255","volume":"191","author":"J Roth","year":"1993","unstructured":"Roth J, Goebeler M, van den Bos C, Sorg C (1993) Expression of calcium-binding proteins MRP8 and MRP14 is associated with distinct monocytic differentiation pathways in HL-60 cells. Biochem Biophys Res Commun 191(2):565\u2013570","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"3375_CR44","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/BOR.0000000000000204","volume":"27","author":"A Huttenlocher","year":"2015","unstructured":"Huttenlocher A, Smith JA (2015) Neutrophils in pediatric autoimmune disease. Curr Opin Rheumatol 27(5):500\u2013504","journal-title":"Curr Opin Rheumatol"},{"issue":"10","key":"3375_CR45","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.38092","volume":"65","author":"S Ringold","year":"2013","unstructured":"Ringold S, Weiss PF, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y, et al. (2013) 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 65(10):2499\u20132512","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3375-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-016-3375-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3375-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3375-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T17:21:02Z","timestamp":1498324862000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-016-3375-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,25]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["3375"],"URL":"https:\/\/doi.org\/10.1007\/s10067-016-3375-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2016,8,25]]}}}